Aerosol Delivery Device Reduces Treatment Time

An improved aerosol delivery device for liquid medications is designed for use by respiratory patients such as those with chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis (CF). The device has been cleared by the U.S. Food and Drug Administration (FDA).

Called eFlow, the cordless device generates a dense aerosol that can be inhaled into the lungs. Treatment time may be reduced from the 10-15 minutes required by traditional nebulizers to as low as three to five minutes, depending on formulation and fill volumes.
The gentle aerosol generation of eFlow has demonstrated the potential to aerosolize suspensions and more fragile molecules, including peptides, proteins, or liposomes, either avoiding or reducing degradation.

"Patients with CF and other chronic lung diseases are tasked with inhaling time-consuming nebulized drugs on a daily basis,” noted David E. Geller, M.D., pediatric pulmonologist at Nemours Children's Hospital in Orlando (FL, USA). "The eFlow may improve their quality of life by providing faster, silent, portable, and versatile aerosol drug delivery.”

The eFlow device was developed by the PARI Aerosol Research Institute (Monterey, CA, USA), a division of PARI GmbH (Munich, Germany), a leading developer of aerosol delivery devices.